Todd Asset Management LLC Has $4.24 Million Stake in Novo Nordisk A/S $NVO

Todd Asset Management LLC lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 35.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 83,329 shares of the company’s stock after buying an additional 21,957 shares during the quarter. Todd Asset Management LLC’s holdings in Novo Nordisk A/S were worth $4,240,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the business. Revolve Wealth Partners LLC boosted its holdings in Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after buying an additional 200 shares during the last quarter. AQR Capital Management LLC raised its holdings in Novo Nordisk A/S by 21.0% during the 1st quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after buying an additional 10,758 shares during the period. Sivia Capital Partners LLC lifted its stake in Novo Nordisk A/S by 18.2% in the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock valued at $712,000 after buying an additional 1,587 shares in the last quarter. Invesco Ltd. increased its position in shares of Novo Nordisk A/S by 26.3% during the second quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock worth $28,967,000 after acquiring an additional 87,467 shares in the last quarter. Finally, Gamco Investors INC. ET AL acquired a new stake in shares of Novo Nordisk A/S during the second quarter worth $314,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $44.91 on Tuesday. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The business’s 50 day moving average price is $40.43 and its two-hundred day moving average price is $46.42. The company has a market cap of $200.52 billion, a PE ratio of 10.54, a price-to-earnings-growth ratio of 4.01 and a beta of 0.77. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The company had revenue of $10.85 billion during the quarter. On average, analysts predict that Novo Nordisk A/S will post 3.46 EPS for the current year.

Analyst Ratings Changes

NVO has been the subject of a number of research reports. Wall Street Zen upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. Kepler Capital Markets lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Tuesday, February 24th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. Finally, Weiss Ratings cut shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Four investment analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.